Michelle Lynn Hall built Eli Lilly's Genetic Medicine group from scratch to more than 140 scientists after leading mRNA modeling work at Moderna, and her path from computational chemistry into RNA therapeutics shapes how she views genetic medicine as an engineering problem built on data, models, and infrastructure rather than something handled case by case. She judges biotech teams by how fast they learn compared to how fast they spend, argues that real advantage in RNA medicine often comes down to hard-won know-how rather than patents alone, and holds her own patent on RNA polymerase variants for co-transcriptional capping.